Aquestive Therapeutics (AQST) Projected to Post Earnings on Monday

Aquestive Therapeutics (NASDAQ:AQST) is expected to be issuing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $10.8960 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million during the quarter, compared to analyst estimates of $13.28 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST traded up $0.05 during trading hours on Monday, reaching $4.25. The stock had a trading volume of 218,856 shares, compared to its average volume of 3,740,455. The business’s fifty day moving average is $4.13 and its two-hundred day moving average is $4.94. The company has a market cap of $527.61 million, a price-to-earnings ratio of -5.44 and a beta of 1.50. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $7.55.

Wall Street Analyst Weigh In

AQST has been the subject of a number of recent research reports. Oppenheimer initiated coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Finally, Lake Street Capital set a $6.00 target price on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of “Buy” and an average price target of $8.80.

Insider Activity

In other Aquestive Therapeutics news, CFO A Ernest Toth, Jr. sold 58,254 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $242,919.18. Following the completion of the transaction, the chief financial officer directly owned 376,112 shares in the company, valued at $1,568,387.04. This represents a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Peter E. Boyd sold 29,814 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total value of $124,324.38. Following the transaction, the insider owned 338,509 shares of the company’s stock, valued at $1,411,582.53. This represents a 8.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 395,690 shares of company stock valued at $1,650,027. 6.81% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AQST. NewEdge Advisors LLC acquired a new position in Aquestive Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets raised its stake in Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares in the last quarter. Modern Wealth Management LLC bought a new stake in shares of Aquestive Therapeutics during the second quarter worth $33,000. Kestra Private Wealth Services LLC bought a new stake in shares of Aquestive Therapeutics during the third quarter worth $60,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Aquestive Therapeutics by 17.0% during the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock worth $72,000 after purchasing an additional 1,862 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.